CORRECTING and REPLACING XPOVIO™ (selinexor) Available for Order at Biologics by McKesson

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on globalbankingandfinance.com is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at globalbankingandfinance.com with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. Globalbankingandfinance.com also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

First sentence of second paragraph of release dated July 8, 2019 should read: XPOVIO is a nuclear export inhibitor indicated in combination with dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory or intolerant to at least two proteasome inhibitors (PI), at least two immunomodulatory agents (IMiD), and an anti-CD38 monoclonal antibody (mAb).1,2

The corrected release reads:

XPOVIO„¢(SELINEXOR) AVAILABLE FOR ORDER AT BIOLOGICS BY MCKESSON

FDA-approved drug is new treatment option for patients with relapsed or penta-refractory multiple myeloma

Biologics by McKesson, an independent specialty pharmacy for oncology and other complex therapeutic areas, announced that it has been selected by Karyopharm Therapeutics, Inc. to be in the limited distribution network for XPOVIO„¢ (selinexor).

XPOVIO is a nuclear export inhibitor indicated in combination with dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory or intolerant to at least two proteasome inhibitors (PI), at least two immunomodulatory agents (IMiD), and an anti-CD38 monoclonal antibody (mAb).1,2 Approved on July 3, XPOVIO was previously granted both Orphan Drug designation and Fast Track designation by the FDA.

We are excited that Biologics is included in the limited network distribution for XPOVIO, said Ann Steagall, director of Clinical Policy at Biologics. We are pleased to be included in the distribution of a first in class XPO inhibitor. Patients who have exhausted the current standard of care therapies now have another option. It is important to us as a premier oncology pharmacy to offer patients and prescribers the newest therapies available.

Biologics is committed to and recognized for its high level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes a pharmacist with in-depth knowledge of disease states and oncology therapies available, an experienced oncology nurse and a financial counselor who is familiar with various financial assistance programs and organizations that help cancer patients. This highly-skilled care team works together to develop individualized care plans that address each patients unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with over 25 years of experience connecting patients to life-changing medications in oncology and other complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics by McKesson delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As part of McKesson Life Sciences, a business within McKesson Corporation, Biologics by McKesson harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.

1BRAND NAME (selinexor) [package insert].

2Data on file. Karyopharm Therapeutics.

McKesson

Claire Crye, Public Relations

281.825.9927 [email protected]